Subtopic Deep Dive
Systemic Immune-Inflammation Index in Oncology
Research Guide
What is Systemic Immune-Inflammation Index in Oncology?
The Systemic Immune-Inflammation Index (SII) is a composite biomarker calculated as platelet count × neutrophil count / lymphocyte count, used to predict prognosis in oncology patients across various malignancies.
SII integrates platelet, neutrophil, and lymphocyte counts from routine blood tests to assess systemic inflammation. Hu et al. (2014) first developed SII for hepatocellular carcinoma (HCC) post-resection, showing superior prognostic value (2135 citations). Validation extended to colorectal cancer (Chen et al., 2017, 699 citations) and cervical cancer (Huang et al., 2019, 405 citations). Meta-analysis by Yang et al. (2018) confirmed SII's prognostic role across cancers (394 citations).
Why It Matters
SII outperforms single markers like NLR or PLR for risk stratification in oncology. In HCC, Hu et al. (2014) demonstrated SII independently predicted survival post-resection. Chen et al. (2017) showed SII identified high-risk colorectal cancer patients within same TNM stages. Huang et al. (2019) validated SII for cervical cancer outcomes. Yang et al. (2018) meta-analysis across cancers linked high SII to worse survival, aiding treatment decisions like chemotherapy intensity.
Key Research Challenges
Optimal SII Cutoff Variability
SII lacks universal cutoffs across cancers, complicating clinical use. Hu et al. (2014) used 160 × 10^9/L for HCC, while Chen et al. (2017) optimized differently for colorectal cancer. Standardization remains unresolved per Yang et al. (2018) meta-analysis.
Validation in Immunotherapy Contexts
SII's role in immunotherapy outcomes needs more data beyond surgery. Capone et al. (2018) linked baseline NLR/dNLR to nivolumab response in melanoma, but SII-specific validation lags. Prospective trials required for integration.
Confounding by Comorbidities
Non-cancer inflammation affects SII accuracy. Templeton et al. (2014) noted PLR elevation in solid tumors linked to poor prognosis but confounded by comorbidities. Nøst et al. (2021) associated systemic markers with cancer incidence, highlighting adjustment needs.
Essential Papers
Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Bo Hu, Xin‐Rong Yang, Yang Xu et al. · 2014 · Clinical Cancer Research · 2.1K citations
Abstract Purpose: We developed a novel systemic immune-inflammation index (SII) based on lymphocyte, neutrophil, and platelet counts and explored its prognostic value in hepatocellular carcinoma (H...
Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases
Agata Buonacera, Benedetta Stancanelli, Michele Colaci et al. · 2022 · International Journal of Molecular Sciences · 843 citations
Over the last 10 years, the evaluation of the neutrophil-to-lymphocyte ratio (NLR) as an emerging marker of diseases has become a compelling field of bio-medical research. Although a precise and un...
Systemic immune-inflammation index for predicting prognosis of colorectal cancer
Jianhui Chen, Ertao Zhai, Yujie Yuan et al. · 2017 · World Journal of Gastroenterology · 699 citations
SII is a more powerful tool for predicting survival outcome in patients with CRC. It might assist the identification of high-risk patients among patients with the same TNM stage.
Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
Arnoud J. Templeton, Olga Ace, Mairéad G. McNamara et al. · 2014 · Cancer Epidemiology Biomarkers & Prevention · 691 citations
Abstract Background: Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in sever...
Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies
Meghan A. Cupp, Margarita Cariolou, Ioanna Tzoulaki et al. · 2020 · BMC Medicine · 646 citations
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone, Diana Giannarelli, Domenico Mallardo et al. · 2018 · Journal for ImmunoTherapy of Cancer · 496 citations
Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values. NLR and dNLR are simple, inexpensive and re...
Systemic inflammation markers and cancer incidence in the UK Biobank
Therese Haugdahl Nøst, Karine Alcala, Ilona Urbárová et al. · 2021 · European Journal of Epidemiology · 465 citations
Reading Guide
Foundational Papers
Start with Hu et al. (2014) for SII invention in HCC (2135 citations), then Templeton et al. (2014) for PLR meta-analysis context (691 citations), Pinato et al. (2012) for related PNI in HCC (410 citations).
Recent Advances
Study Chen et al. (2017, colorectal, 699 citations), Huang et al. (2019, cervical, 405 citations), Yang et al. (2018, meta-analysis, 394 citations), Capone et al. (2018, immunotherapy links, 496 citations).
Core Methods
SII calculation from blood counts; multivariate Cox models for independence; ROC for cutoffs; Kaplan-Meier survival curves (Hu et al., 2014; Chen et al., 2017).
How PapersFlow Helps You Research Systemic Immune-Inflammation Index in Oncology
Discover & Search
Research Agent uses searchPapers('Systemic Immune-Inflammation Index oncology prognosis') to retrieve Hu et al. (2014) as top hit (2135 citations), then citationGraph reveals forward citations like Chen et al. (2017), and findSimilarPapers expands to Huang et al. (2019). exaSearch drills into meta-analyses like Yang et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent on Hu et al. (2014) to extract SII formula and hazard ratios, then verifyResponse with CoVe cross-checks claims against Chen et al. (2017). runPythonAnalysis recreates Kaplan-Meier curves from reported counts using pandas survival analysis. GRADE grading scores Hu et al. (2014) as high-quality prognostic evidence.
Synthesize & Write
Synthesis Agent detects gaps like SII-immunotherapy links via contradiction flagging between surgical (Hu et al., 2014) and immunotherapy papers (Capone et al., 2018). Writing Agent uses latexEditText for methods sections, latexSyncCitations integrates 10+ SII papers, latexCompile generates polished reviews. exportMermaid visualizes SII vs. NLR/PLR comparison flowcharts.
Use Cases
"Reproduce SII survival analysis from Hu et al. 2014 HCC data"
Research Agent → searchPapers → readPaperContent (Hu et al.) → Analysis Agent → runPythonAnalysis (pandas lifelines Kaplan-Meier on platelet/neutrophil/lymphocyte counts) → matplotlib survival plots output.
"Write LaTeX review of SII in gastrointestinal cancers"
Research Agent → citationGraph (Hu/Chen papers) → Synthesis → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → PDF with SII formula tables.
"Find code for SII calculator from recent papers"
Research Agent → searchPapers('SII calculator github') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified R/Python SII scripts with cutoff optimization.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ SII oncology papers) → citationGraph clustering → GRADE all → structured report with meta-hazard ratios. DeepScan applies 7-step analysis: readPaperContent(Hu et al.) → verifyResponse(CoVe on cutoffs) → runPythonAnalysis(replications) → synthesis gaps. Theorizer generates hypotheses like 'SII + PD-L1 for immunotherapy stratification' from Hu/Capone papers.
Frequently Asked Questions
What is the SII formula?
SII = (platelet count × neutrophil count) / lymphocyte count, all per microliter (Hu et al., 2014).
What methods validate SII in oncology?
Cox regression and Kaplan-Meier analyses in resected HCC (Hu et al., 2014), colorectal cancer (Chen et al., 2017), and meta-analysis across cancers (Yang et al., 2018).
What are key SII papers?
Hu et al. (2014, 2135 citations, HCC origin), Chen et al. (2017, 699 citations, colorectal), Huang et al. (2019, 405 citations, cervical), Yang et al. (2018, 394 citations, meta-analysis).
What are open problems in SII research?
Standard cutoffs, immunotherapy validation, comorbidity adjustments (Yang et al., 2018; Capone et al., 2018).
Research Inflammatory Biomarkers in Disease Prognosis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Systemic Immune-Inflammation Index in Oncology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers